Einsatz von monoklonalen Antikörpern in der Migräneprophylaxe

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

AutorIn: Dr. Herta Artemian

Neurologische Abteilung, Krankenhaus Vöcklabruck


AutorIn: Prim. Priv.-Doz. Dr. Nenad Mitrovic

Neurologische Abteilung, Krankenhaus Vöcklabruck


Zusammengestellt für den Beirat „Schmerz“


1 Dodick DW et al., Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014; 13:885–92
Weitere Literatur:
– Goadsby PJ, Therapeutic prospects for migraine: can paradise be regained? Ann Neurol 2014; 74:423–34
– Goadsby PJ et al., Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 1988; 23:193–6
– Hewitt DJ et al., Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31:712–22
– Juhasz G et al., Sumatriptan causes parallel decreasein plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia 2005; 25:179–83
– Lassen LH et al., CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54–61
– Lipton RB, Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011; 51 Suppl 2:77–83
– Murray CJ et al., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197–223
– Munakata J et al., Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009; 49:498–508
– Natoli JL et al., Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010; 30:599–609

neuro 03|2014

Herausgeber: Österreichische Gesellschaft für Neurologie, Univ.-Prof. Dr. Reinhold Schmidt, Präsident der ÖGN
Publikationsdatum: 2014-10-20